Ataluren-PTC124-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAtalurenCat. No.: HY-14832CAS No.: 775304-57-9Synonyms: PTC124分式: CHFNO分量: 284.24作靶點: CFTR作通路: Membrane Transporter/Ion Channel儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 52 mg/mL (182.

2、94 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.5182 mL 17.5908 mL 35.1815 mL5 mM 0.7036 mL 3.5182 mL 7.0363 mL10 mM 0.3518 mL 1.7591 mL 3.5182 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Ataluren (PTC124)可服的 CFTR-G542X 義等位基

3、因抑制劑。IC50 & Target CFTR 1體外研究This premature “stop” signal (a class I mutation) prevents the cell from producing a full-length CFTR protein1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE1. Ataluren (PTC124)-a new chemical entity that selectively induces ribosomal readthrough of prematurebut not nor

4、mal termination codons 2.體內(nèi)研究 Ataluren (PTC124) activity, optimized using nonsense-containing reporters, promotes dystrophin productionin primary muscle cells from humans and mdx mice expressing dystrophin nonsense alleles, and rescuesstriated muscle function in mdx mice within 2-8 weeks of drug exp

5、osure. Ataluren (PTC124) is well toleratedin animals at plasma exposures substantially in excess of those required for nonsense suppression 2. Toinduce nonsense suppression and increase PPT1 enzyme activity, the read-through drug Ataluren (PTC124)is given via intraperitoneal (i.p.) injection to male

6、 Cln1R151X mice at 2 months of age. These treatments areperformed four times daily for 2 consecutive days in a proof-of-principle study. Used at 10 mg/kg, Ataluren(PTC124) increased PPT1 enzyme activity (P=0.0001 by unpaired t-test) and protein level (P=0.0014 byunpaired t-test) in the liver, but di

7、d not increase PPT1 enzyme activity or protein level in the cortex. Thistissue-specific effect is likely due to the inability of Ataluren (PTC124) to breach the blood brain barrier (BBB),which decreased the bioavailability of Ataluren (PTC124) within the brain, and prevented Ataluren (PTC124)from re

8、aching an efficacious concentration within the therapeutic window 3.PROTOCOLCell Assay 2 Duplicate samples of HEK293 cells harbouring LUC-190 (UGA) are incubated in the presence of 5 MAtaluren (PTC124) (treated) or 1% DMSO (untreated) for 20 h. The cells are collected, washed twice inphosphate buffe

9、red saline (PBS), resuspended in sample buffer (Bio-Rad) and shipped on dry ice toKendrick Laboratories for two-dimensional electrophoretic analysis Isoelectric focusing (pH 3.5-10) is carriedout in glass tubes for 20,000 V-hours. One g of a tropomyosin internal standard is added to each sample.Seco

10、nd dimension SDS slab gel electrophoresis is carried out for approximately 6 h at 25 mA per gel. Afterelectrophoresis, gels are transferred to PVDF paper. Computerized analysis of spot mobility used Phoretixsoftware 2.MCE has not independently confirmed the accuracy of these methods. They are for re

11、ference only.Animal Mice 3Administration 3 Male mice are randomly assigned to either a treatment group or vehicle control group. Six to eight mice pergroup are treated with 10 or 100 mg/kg Ataluren (PTC124) dissolved in PBS containing DMSO (2% for 10mg/kg and 20% for 100 mg/kg) and (2-hydroxypropyl)

12、-cyclodextrin (22%) via intraperitoneal (i.p.) injectionsfour times daily for 2 consecutive days. Six to eight control mice are treated with the vehicle of the drug: PBScontaining DMSO (2% or 20%) and (2-hydroxypropyl)-cyclodextrin (22%). Immediately following the lastinjection on the second day, ti

13、ssues are collected and stored at 80C for further use.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Biopolymers. 2014 Apr;101(4):391-7.See more customer validations on HYPERLINK / www.MedChemE2/3 Master of Small Molecules 您邊的抑制劑師www.MedChe

14、mEREFERENCES1. Pettit RS, et al. CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11.2. Welch EM, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature, 2007, 447(7140), 87-91.3. Miller JN, et al. The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppressiontherapy. Hum Mol Genet. 2015 Jan 1